StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera Genetic Testing Services by Year

Genetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025] ($M)

Natera Genetic Testing Services: $13.7M in FY2023, up 28.0% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
13.7
Period ended Dec 31, 2023
Change on a year earlier
+28.0%
10.7 in FY2022
History
2 years
Since FY2022
Sources
2
Documents cited below

Where the FY2023 figure comes from

Source: Form 10-K (2024-02-29) ↗

Reported in Form 10-K/10-Q Note — Revenue Recognition (2022–2025Q3).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedGenetic Testing Services — Current Contract Liability ($M) [legacy through Q3 2025] ($M)Year on yearSource
FY2023Dec 31, 202313.7+28.0%Form 10-K (2024-02-29) ↗
FY2022Dec 31, 202210.7–Form 10-K (2023-03-01) ↗

Cite this data

StockData. (2026). Natera Genetic Testing Services ($M), annual FY2022–FY2023 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-genetic-testing-current

See every metric in the Natera KPI table. Data updated Nov 2, 2026.